Breast Cancer Market Sees Rapid Growth — Key Insights And Forecasts Of Different Breast Cancers For The Coming 10 Years | Delveinsight
The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...
stocknews1d
3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine
The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...
The Lancet1d
Trastuzumab rezetecan, a new antibody–drug conjugate in HER2-mutated NSCLC
HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...
FiercePharma1d
Jazz 'active and looking' at M&A deals of 'various sizes' as it wraps up Epidiolex patent fights: execs
Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought ...
FDA accepts Teva & Medincell’s UZEDY sNDA for extended-release to treat BP-I
Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...
BioPharma Dive3d
Mirum drug for rare genetic disease gains FDA approval
Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with ...
FierceBiotech3d
Entrada's 2-year ordeal ends as FDA lifts hold on DMD drug
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
pharmaphorum7d
Boehringer eyes third quarter FDA verdict for oral HER2 drug
AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has accelerated approval as a second-line treatment for HER2-mutated NSCLC and is dosed ...
Cure Today8d
Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...
precisionmedicineonline8d
FDA Accepts Boehringer Ingelheim's New Drug Application for HER2-Targeted Therapy in NSCLC
In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.
BioSpace8d
5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...